Highlights

  • On 24 July 2026 Immutep confirmed an abstract had been accepted for ESMO Congress 2026, held in Madrid from 23 to 27…
  • Chief executive Marc Voigt said the company was "very disappointed and surprised with the outcome of the futility analysis, in light…
  • The June quarter report, lodged 30 July 2026, put cash, cash equivalents and term deposits at AUD 68.87 million, down from AUD…
  • Root cause findings are expected in the third quarter of calendar 2026, with IMP761 trial updates guided for the second half.

Immutep will present at the European Society for Medical Oncology Congress in Madrid this October, its first notable conference appearance since a Phase III failure in March erased nine-tenths of its Market Value . The abstract is a quality of life analysis from an investigator-initiated sarcoma study, not a registrational readout.

Company Overview

Immutep is a Sydney-headquartered biotechnology company built around Lymphocyte Activation Gene-3, or LAG-3, a target it has worked on for more than two decades through its French Subsidiary Immutep S.A.S. Its lead candidate, eftilagimod alfa (efti), is a soluble LAG-3 protein the company describes as a first-in-class MHC Class II agonist. Rather than blocking a checkpoint, efti activates antigen-presenting cells to drive a broader T-cell response, and has been trialled with PD-1…

Recent Developments

On 24 July 2026 Immutep confirmed an abstract had been accepted for ESMO Congress 2026, held in Madrid from 23 to 27 October. The presentation is an ePoster, numbered 3788eP, covering health-related quality of life outcomes from EFTISARC-NEO, an investigator-initiated Phase II trial combining efti with pembrolizumab and radiotherapy in neoadjuvant soft tissue sarcoma. That study has met its primary immune activation objective and secured FDA Orphan Drug …

The event that defines the current position occurred earlier. On 13 March 2026 Immutep announced that the independent data monitoring committee for TACTI-004, its Phase III trial of efti plus pembrolizumab and chemotherapy in first-line non-small cell lung cancer, had recommended discontinuation after a planned interim futility analysis. The trial had enrolled roughly half of a targeted 756 patients across about 140 sites in 27 countries. With 173…

Financial Snapshot

The June quarter report, lodged 30 July 2026, put cash, cash equivalents and term deposits at AUD 68.87 million, down from AUD 99.1 million at 31 December 2025. Net operating cash outflow for the quarter was AUD 38.9 million, against a AUD 13.5 million inflow in the March quarter. Research and Development consumed AUD 22.0 million, up from AUD 11.8 million…

Other pipeline data points were more constructive. Mature overall survival data from INSIGHT-003 in first-line non-squamous NSCLC showed a median of 30.9 months across 51 evaluable patients, 92 % of whom had PD-L1 scores below 50 %. AIPAC-003 in metastatic breast cancer completed, with last patient follow-up closing on 30 June 2026. IMP761 met its primary safety endpoint in Phase I…

What to Watch

Root cause findings are expected in the third quarter of calendar 2026, with IMP761 trial updates guided for the second half. The ESMO ePoster follows on 23 to 27 October, abstracts published online on 19 October. Further data from AIPAC-003 remains possible now follow-up has closed.

Risks

The central risk is that the root cause analysis produces no actionable explanation, leaving efti without a credible registrational path; no new efti studies will begin until that work concludes. Financing risk is real despite the stated runway, since raising Equity at 4.9 cents would be heavily dilutive, and the Novartis termination removes a potential income line. The Dr. Reddy's collaboration survived the discontinuation but has already required a USD…

Outlook

Immutep enters the second half of 2026 as a very different proposition from a year ago: cash-backed, cost-reduced, and with a lead asset under internal review. The October ESMO ePoster is a verified event, but it is quality-of-life data from a small sarcoma trial rather than a readout that resets a valuation. The root cause findings, and what…